Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
    • Sjögren’s Disease
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Calcium Pyrophosphate Deposition Disease: The Great Mimic

Bryn Nelson, PhD  |  Issue: July 2025  |  July 9, 2025

In addition, imaging can reveal evidence of bulky bone spurs on the metacarpals of the hand and chondrocalcinosis in cartilage, such as the triangular fibrocartilage complex of the wrist. Dr. Bettendorf cautions, however, that chondrocalcinosis can appear in a patient who has never had any signs or symptoms of CPPD, like the asymptomatic older patients in the 1975 study, meaning that imaging alone isn’t always sufficient for a diagnosis. “I think about it as one piece of the puzzle, but really what we need is that fluid from around the joint and making sure that we confirm the correct diagnosis,” she says.

Here too, treatment options have been steadily expanding. “For this chronic inflammatory type, we use the same drugs as we use for osteoarthritislike phenotypes, but in higher doses,” Dr. Rosenthal says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Colchicine has worked well for treating some of Dr. Bettendorf’s patients. As with rheumatoid arthritis, doctors have also administered disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate and hydroxychloroquine, although with more variable results. Some have experimented with drug combinations that include prednisone and colchicine. Limited evidence has suggested IL-6 inhibitors and IL-1 beta inhibitors used to treat rheumatoid arthritis may have utility here as well.

Rarities & Risk Factors

In rare cases, Dr. Rosenthal says, CPPD can resemble neuroarthropathy, which involves a sensory nerve abnormality that causes a loss of sensation and extensive joint damage, most often in the ankle or foot. Alternatively, the crystal deposition can be in a tophus-like or cluster-like formation within the body’s soft tissue, giving it the appearance of a tumor.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Bettendorf has even seen CPPD cases involving the temporomandibular joint, which attaches the lower jaw to the skull, or the odontoid process of the cervical spine, where ligaments attach to the upper portion of the spinal column.

“When that happens, it can actually have a pseudo-meningitis type of presentation, [in which] somebody might have low-grade fevers, difficulty moving their head or their neck, and severe pain with that—and it looks, for all the world, like meningitis,” says Dr. Bettendorf. A negative spinal tap, however, can prompt doctors to order imaging that reveals calcium pyrophosphate crystals surrounding the odontoid process. “When that happens, that can be a scarier presentation, but it’s something that we can treat.”

Although CPPD’s etiology and the mechanisms leading to its many forms remain uncertain, researchers have identified four main classes of risk factors. First, advanced age increases the risk for the sporadic form of the disease. Second, four metabolic diseases that result in the mishandling of pyrophosphate can also increase risk. Dr. Rosenthal calls them the four Hs: hemochromatosis (excess iron absorption), hypophosphatasia (low levels of alkaline phosphatase), hypomagnesemia (low magnesium levels), and hyperparathyroidism (excess parathyroid hormone). A fifth condition, hypothyroidism, was once thought to be associated as well, but research now suggests it is not.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline ArthritisOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:arthrocentesiscalcium pyrophosphate deposition diseasechondrocalcinosisColchicineCorticosteroidscrystal arthritisGoutGout Resource CenterinflammationOsteoarthritispseudogoutRheumatoid arthritis

Related Articles

    New Insights into CPPD

    October 1, 2013

    Progress in research, outcomes, diagnosis, and treatment of calcium pyrophosphate dihydrate crystal deposition disease

    ACR Convergence graphic

    New Clinical Insights into the Pathogenesis, Diagnosis & Treatment of Calcium Pyrophosphate Arthritis

    December 17, 2020

    New diagnostic approaches combined with new evidence about pathogenesis are providing opportunities to help rheumatologists manage calcium pyrophosphate deposition disease.

    Case Report: CPPD Presenting as Pseudosepsis

    September 6, 2022

    Calcium pyrophosphate crystal deposition disease (CPPD) is an arthritis caused by the accumulation of calcium pyrophosphate crystals. Despite a prevalence of 4–7% among the adult population in Europe and the U.S., it has remained a relatively under-recognized disease owing to its many clinical presentations.1 CPPD may cause an acute mono/oligoarthritis, which may mimic gout or…

    Pseudo-What? Exploring the Classification Criteria Development Process for CPPD

    December 12, 2022

    PHILADELPHIA—The term pseudogout has been a source of confusion among rheumatologists, especially as our understanding of calcium pyrophosphate crystal deposition (CPPD) disease has become more nuanced. This condition has many complex and interesting facets that warrant closer investigation. An ACR Convergence 2022 session sought to update the audience on the progress to date in developing…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences